Early-life microbiota diversification facilitates enterocyte proliferation
The adult gastrointestinal tract is colonized by trillions of bacteria that influence cellular homeostasis through microbial metabolism of dietary and hepatic compounds. The microbiota ecosystem and associated metabolic networks are gradually established in the first years of life (2-3 years) beginning at birth. In healthy term infants, lactic-acid producing bacteria typically colonize the gut shortly after or during delivery and gradually increase in abundance with limited diversity throughout infancy. Delivery at earlier gestational ages (pre-term) is associated with expedited microbiota diversification and altered metabolic profiles in the gut. Evidence from germ-free mouse models has shown that microbial acquisition in the gut facilitates tissue growth and organization of the crypt-villus architecture associated with a mature intestinal tract. However, it remains unclear if distinct patterns of term and pre-term microbiome maturation confer functional changes in the developing small intestine.
Two neonatal intensive care unit physicians, Dr. Oleksandr Kudin and Dr. Josef Neu had access to fecal samples from term and pre-term patients and shared our interest in elucidating host response to neonatal microbiota. Dr. Kudin joined our research group as part of his research fellowship, and together we optimized organoid cultures for in vitro screening of microbial metabolites from patient fecal samples. Simultaneously, other publications demonstrated that lactate (derived from lactic acid producing bacteria in the term gut or from ingested milk) induces enterocyte proliferation, while structural proteins from bacteria (lipopolysaccharide, flagellin) activate toll-like receptor signaling and inflammatory responses. Given this evidence, we expected pre-term microbial communities to induce an inflammatory response while term microbial metabolites would facilitate epithelial maturation.
We first characterized microbial and metabolic composition in term and pre-term cohorts. As expected, term samples harbored microbial communities characterized primarily by lactic-acid producing bacteria (LAB). In contrast, the pre-term microbiome was more diverse and lacking prominent LAB species. The pre-term cohort exhibited a significantly higher metabolic capacity, notably including significant increases in secondary bile acids. These biotransformed bile acids have been shown to increase proliferation and epithelial regeneration following chemical-induced injury. Mapping metabolomics profiles to microbial KEGG pathways showed a significant increase in amino acid and vitamin biosynthetic pathways with a concomitant increase in overall metabolite concentrations.
To examine how these metabolites functionally affect the intestinal epithelium, we cultured small intestinal organoids with term and pre-term fecal metabolites. These organoids form “mini-guts” derived from intestinal stem cells which recapitulate epithelial morphology and cellular heterogeneity. Surprisingly, when cultured in the presence of pre-term fecal metabolites, we observed increased proliferation (fig. 1) and stem cell activation relative to term fecal metabolites without activation of inflammatory signaling pathways.
Organoid models are an increasingly common and powerful tool for defining host-microbe interactions intrinsically linked to the biology of the intestinal epithelium. Recently, human organoids have been used to identify the functional effects of individual microbial metabolites and characterize mutational profiles after exposure to bacterial genotoxins. Our study demonstrates the capability to induce functional changes associated with entire microbial ecosystems in vitro using host fecal material. This approach may help clarify complex metabolic interactions between host and microbes in intestinal diseases such as colon cancer.
For more details, please refer to our paper.
Follow the Topic
-
BMC Microbiology
This is an open access, peer-reviewed journal that considers articles on all microorganisms - bacteria, archaea, algae and fungi, viruses, unicellular parasites and helminths.
Related Collections
With collections, you can get published faster and increase your visibility.
Phage therapy in the age of antimicrobial resistance
The spread of antimicrobial resistance presents a major global challenge, with multi-drug resistant pathogens posing a significant threat to public health due to the reduced efficacy of many antibiotics against common infections. Bacteriophages (or simply, phages) are viruses that infect bacteria, offering an alternative to antibiotics. In this context, phage therapy, which is the use of bacteria-specific phages to treat bacterial infections, has gained renewed interest and relevance as a promising avenue for combating multi-drug resistant pathogens. Due to the specificity of phages for their bacterial hosts, phages can target specific bacterial strains and provide a targeted therapeutic approach to combat antimicrobial resistance. Research in this field encompasses the study of the structure and evolution of phage-bacteria interactions, host specificity, resistance mechanisms, phage products, treatment efficacy, and the clinical use and regulations of phage therapy.
In support of the UN Sustainable Development Goal 3 (SDG 3), ‘Good health and well-being’, BMC Microbiology announces the launch of the Collection Phage therapy in the age of antimicrobial resistance. This Collection seeks to understand and explore the potential, as well as the limitations, of phage therapy as a promising approach to fight antimicrobial resistance. We encourage submissions that report for instance on phage-bacteria interactions, clinical applications of phage therapy, bacteriophage resistance mechanisms and evolution of resistance mechanisms, phage lysins and their therapeutic potential, among other research questions. Researchers and experts in the field are invited to submit research articles that cover, but are not limited to, the following topics:
Phage-bacteria interactions and host specificity
Host response to phage infection
The antimicrobial potential of bacteriophages and phage-borne lysins
Applications of bacteriophages and phage enzymes to modulate and treat bacterial infections
Challenges and opportunities in the development and implementation of phage therapy against multi-drug resistant pathogens
Precision medicine applications of phage therapy
Phage-antibiotic synergy
Phage cocktails against multi-drug resistant bacteria
Phage therapy clinical trials
Phages in biofilm control
Mechanisms and regulation of lytic, lysogenic and chronic cycles of bacteriophages
Regulation of phage gene expression
Bacteriophage genomes
Control of phage genome replication
Biocontrol capabilities of phages
Mechanisms underlying treatment efficacy and the evolution of resistance
Bacteriophage diversity, genomics and phylogeny
Bacteriophage resistance mechanisms
Bacterial anti-phage systems
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Apr 30, 2025
Digitalization in infectious disease control measures
Outbreaks of infectious diseases are unpredictable and can have major detrimental impacts and long-lasting effects on human society and public health. The digitalization and digital surveillance systems applied to develop infectious disease control measures have emerged as a transformative approach in public health, potentially capable to improve the way we monitor, diagnose, control and communicate about infectious diseases. From digital epidemiology and real-time monitoring to the use of computational modeling and machine learning for predicting disease spread and prevention strategies, the integration of technology and laboratory research represents a powerful tool to understand the epidemiology of infectious diseases.
Emerging technological developments in laboratory and epidemiologic methods, combined with the use of big data, increasing computational power and applications of machine learning/artificial intelligence can significantly improve how we study and control the spreading of infectious diseases and zoonoses. In support of the UN Sustainable Development Goal 3 (SDG 3), ‘Good health and well-being’, BMC Microbiology welcomes submissions to the collection, Digitalization in infectious disease control measures. The collection aims to explore the innovative use of digital technologies in infectious disease surveillance and control, as well as diagnosis. Research must focus on infectious diseases and be in scope for the journal. Manuscripts focusing exclusively on digital technologies and tools, as well as on digital communication, will not be considered. We invite researchers to submit research articles that cover, but are not limited to, the following topics:
Infectious disease digital surveillance to prevent and control outbreaks
Development and use of digital data and technology for epidemiological research and infectious disease tracking
Big data and digital platforms for infectious disease surveillance and modeling
Computational modeling to study the complex behavior of infectious diseases
Machine learning and artificial intelligence applications/tools for predicting and preventing the spreading of infectious diseases
Development and applications of digital tools for the diagnosing of infectious diseases
Advances in real-time monitoring of infectious diseases for early detection and response
Development and use of cloud computing for infectious disease surveillance and control, including data security and federated data governance
Digital technologies applied to One Health approach
Potential barriers and solutions for the adaptation of digital technologies applied to infectious disease surveillance and control by decision-makers
Applications of digital twin technology towards infectious diseases
Incorporating socio-behavioral mechanisms to study transmission and disease risks
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: May 31, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in